| Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor α and matrix metalloproteinase 7 expression, migration … P Chieng-Yane, A Bocquet, R Létienne, T Bourbon, S Sablayrolles, ... Journal of Pharmacology and Experimental Therapeutics 336 (3), 643-651, 2011 | 59 | 2011 |
| Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes C Pinet, V Algalarrondo, S Sablayrolles, B Le Grand, C Pignier, D Cussac, ... Molecular pharmacology 73 (6), 1622-1631, 2008 | 25 | 2008 |
| F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy B Le Grand, R Letienne, E Dupont-Passelaigue, F Lantoine-Adam, ... Naunyn-Schmiedeberg's archives of pharmacology 387, 667-677, 2014 | 10 | 2014 |
| Anti‐fibrillatory effects of F17727, a new IKur blocker, in rats and rabbits with myocardial infarction or heart failure (652.17) D Junquero, A Latil, R Letienne, C Pignier, Y Verscheure, N Mougenot, ... The FASEB Journal 28, 652.17, 2014 | 1 | 2014 |
| Inhibitors of the protease-activated receptor-1 reduce the atrial remodelling in a rat model of chronic heart failure C Jumeau, P Chieng-Yane, B Le Grand, S Hatem, M Dufilho FUNDAMENTAL & CLINICAL PHARMACOLOGY 27, 40-40, 2013 | | 2013 |
| F 16915 prevents heart failure induced atrial structural remodelling: a promising new drug as up-stream therapy for atrial fibrillation C Pignier, R Letienne, F Lantoine-Adam, M David-Dufilho, S Hatem, ... EUROPEAN HEART JOURNAL 33, 815-816, 2012 | | 2012 |
| F16618, an antagonist of the protease activated receptor 1 reduces the atrial remodeling in a rat model of Chronic Heart Failure M Dufilho, P Chieng-Yane, C Jumeau, N Mougenot, B Le Grand, ... EUROPEAN HEART JOURNAL 33, 115-115, 2012 | | 2012 |
| Thrombomodulin activates ErbB signaling to inhibit PAR-1-induced monocyte adhesion P Chieng-Yane, S Hatem, M David-Dufilho FUNDAMENTAL & CLINICAL PHARMACOLOGY 26, 5-5, 2012 | | 2012 |
| Protease activated receptor-1 antagonist, f 16618 reduces arterial restenosis by down-regulation of tnf alpha and mmp7 expression, and migration and proliferation of vascular … P Chieng-Yane, A Bocquet, R Letienne, T Bourbon, S Sablayrolle, ... FUNDAMENTAL & CLINICAL PHARMACOLOGY 25, 17-18, 2011 | | 2011 |
| F 16618, A New Par1 Antagonist Prevents Restenosis by Inhibiting Migration and Proliferation of Smooth Muscle Cells. P Chieng Yane, A Bocquet, R Létienne, T Bourbon, S Sablayrolles, ... Circulation 122 (suppl_21), A14339-A14339, 2010 | | 2010 |
